Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
24.06. | Cosmos Health begins US manufacturing with DolCas Biotech | 3 | Investing.com | ||
24.06. | Cosmos Health startet US-Produktion mit DolCas Biotech | 3 | Investing.com Deutsch | ||
24.06. | Cosmos Health Inc.: Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech | 246 | GlobeNewswire (Europe) | CHICAGO, June 24, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
03.06. | Cosmos Health Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
COSMOS HEALTH Aktie jetzt für 0€ handeln | |||||
15.05. | Cosmos Health Inc.: RETRANSMISSION - Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven | 894 | GlobeNewswire (Europe) | CHICAGO, May 15, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
15.05. | Cosmos Health Inc.: Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven | 325 | GlobeNewswire (Europe) | CHICAGO, May 15, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
15.05. | Cosmos Health Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
07.05. | Cosmos Health Inc.: Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units | 328 | GlobeNewswire (Europe) | CHICAGO, May 07, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
07.05. | Cosmos Health Inc. - 8-K, Current Report | 2 | SEC Filings | ||
06.05. | Cosmos Health erhält NASDAQ-Fristverlängerung für Compliance | - | Investing.com Deutsch | ||
06.05. | Cosmos Health granted Nasdaq compliance extension | 1 | Investing.com | ||
06.05. | Cosmos Health Inc.: Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq | 279 | GlobeNewswire (Europe) | CHICAGO, May 06, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
30.04. | Cosmos Health CEO boosts stake with $526,000 share purchase | 1 | Investing.com | ||
30.04. | Cosmos Health CEO erhöht Beteiligung durch Aktienkauf im Wert von 526.000 US-Dollar | 2 | Investing.com Deutsch | ||
30.04. | Cosmos Health Inc.: Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 | 325 | GlobeNewswire (Europe) | CHICAGO, April 30, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
16.04. | Cosmos Health Inc.: Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million | 319 | GlobeNewswire (Europe) | CHICAGO, April 16, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
15.04. | Cosmos Health Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
09.04. | Cosmos Health sichert Vertrag für Antiseptika-Produktion | 1 | Investing.com Deutsch | ||
09.04. | Cosmos Health secures deal for antiseptic drug production | 2 | Investing.com | ||
09.04. | Cosmos Health Inc.: Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L | 431 | GlobeNewswire (Europe) | CHICAGO, April 09, 2025 ("Cosmos Health" or the "Company')
, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVO NORDISK | 59,28 | -0,10 % | Investor Woche: The Metals Company will Tiefseebergbau erobern, Novo Nordisk unter Druck, NVIDIA und Microsoft auf Allzeithoch, US-Anleihenachfrage schwach, Euro stark, RTL kauft Sky | Die Märkte entspannen sich, USD und langfristige US-Anleihen bleiben unter Druck. Tiefseebergbauspezialist TMC mit historischer Rallye, während Novo Nordisk unter Druck gerät. RTL kauft Sky Deutschland... ► Artikel lesen | |
PFIZER | 21,415 | +0,85 % | Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen | ||
NOVARTIS | 105,04 | +0,32 % | UBS stuft NOVARTIS AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Novartis auf "Neutral" belassen. In den USA könnte der Markteintritt von Generika zum Medikament Entresto von Novartis gegen... ► Artikel lesen | |
AURORA CANNABIS | 3,805 | +4,82 % | Aurora Cannabis Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
CANOPY GROWTH | 1,046 | +8,62 % | Canopy Growth Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
ELI LILLY | 659,70 | -1,26 % | Eli Lilly | Rolls-Royce | VW - Rücksetzer bei Palantir ausnutzen? | Markus Weingran - Mein Tipp: SMARTBROKER+: https://dwbdiv.smartbrokerplus.de/ts/94450/tsc - typ=r&amc=con.smartbrokerplus.536232.548190.CRTuFopWREk&smc1=YouTube (Werbung) Willkommen bei der Börsenlounge... ► Artikel lesen | |
MERCK & CO | 69,70 | +0,43 % | Merck & Co.: Patente, Prognosen und eine fatale Fehleinschätzung | Auslaufende Patente, geopolitische Risiken, Abschreibungen. Merck steht unter Druck, doch abseits der Schlagzeilen läuft das Geschäft erstaunlich gut Den vollständigen Artikel lesen ... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
TILRAY BRANDS | 0,380 | +6,98 % | Tilray Brands, Inc.: Tilray Medical erhält vom italienischen Gesundheitsministerium die erste Genehmigung für den Vertrieb von medizinischen Cannabisblüten für therapeutische Zwecke | SAVONA, Italien, June 25, 2025 (GLOBE NEWSWIRE) -- Tilray Medical ("Tilray"), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und weltweit führender Anbieter von medizinischem... ► Artikel lesen | |
TEVA | 14,500 | +2,47 % | Formycon vergibt Deutschland-Vertrieb von FYB202 an Teva-Sparte ratiopharm | Die Formycon AG hat eine Vereinbarung mit der Teva-Tochter ratiopharm geschlossen, die das Ustekinumab-Biosimilar FYB202 unter dem Namen Fymskina ab dem dritten Quartal 2025 in Deutschland vermarkten... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 385,90 | +0,59 % | Vertex Pharmaceuticals Incorporated: Vertex Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis | - ALYFTREK(deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for... ► Artikel lesen | |
INNOCAN PHARMA | 0,139 | -1,42 % | InnoCan Pharma: Mega-News im Anmarsch? | ||
ABBOTT LABORATORIES | 114,10 | -1,26 % | Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion | ||
ARZNEIWERK AG VIDA | 0,570 | -3,39 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 30.06.2025 | The following instruments on XETRA do have their last trading day on 30.06.2025Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 30.06.2025ISIN NameDE000A3EX3G0 GORE German Office... ► Artikel lesen | |
CRONOS GROUP | 1,605 | 0,00 % | Cronos grows international footprint in Switzerland |